207129-69-9

Upstream product

• 41239-10-5 N-(2-bromoethyl)methylamine 
• 207129-54-2 (3aS,4R,8R,8aS)-5,7-Dibenzyl-4,8-bis-(4-hydroxy-benzyl)-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 100-39-0 benzyl bromide 
• 207129-50-8 (4R,5S,6S,7R)-1,3-Dibenzyl-4,7-bis-(4-methoxy-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 207129-49-5 (4R,5S,6S,7R)-4,7-Bis-(4-methoxy-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 167827-16-9 (4R,5S,6S,7R)-1,3-Dibenzyl-5,6-dihydroxy-4,7-bis-(4-methoxy-benzyl)-[1,3]diazepan-2-one 
• 207129-57-5 (3aS,4R,8R,8aS)-5,7-Dibenzyl-4,8-bis-(4-methoxy-benzyl)-2,2-dimethyl-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 167827-20-5 (4R,5S,6S,7R)-1,3-Dibenzyl-5,6-dihydroxy-4,7-bis-(4-hydroxy-benzyl)-[1,3]diazepan-2-one 

Relevant academic research and scientific papers

The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: Modifications of the P1/P1' residues

Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity. Compounds 8b, 10 (3- and 4-pyridylmethyl analogs) and 6b (4-methoxy analog) showed significant improvement in antiviral activity relative to lead compounds DMP323 and DMP450.